menu

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer

close
FDA D.I.S.C.O.: First Biosimilar Approval for the Treatment of Cancer
RestartResume
Choose a format
Media formats available:
Details
Comments
  • Overview

    Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

    Released on December 21, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    Oncologists Dr. Sanjeeve Bala and Dr. Abhilasha Nair from FDA’s Oncology Center of Excellence discuss the recent approval of bevacizumab-awwb, a biosimilar to US-licensed Avastin, marketed as MVASI. MVASI is the first biosimilar approved in the US for the treatment of cancer.

    Released on December 21, 2017

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 2/20/20